🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesDo the heart benefits go away if I stop taking it? — looking for input Page 7

Do the heart benefits go away if I stop taking it? — looking for input

DeniseRN_TPA Sat, Oct 19, 2024 at 12:02 AM 45 replies 2,308 viewsPage 7 of 9
hannah_MT
New Member
23
89
Feb 2026
Bozeman, MT
Feb 12, 2025 at 5:44 PM#31
josh_phd_bmore said:
Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history.

Senior perspective on cardiovascular risk: I'm 69 years old and started this journey skeptically. My geriatrician recommended it after years of failed interventions.

9 months later: down 47 lbs, more mobile, pain reduced, medications simplified. My quality of life has improved dramatically. I wish this existed 20 years ago.

To other older adults hesitating: the SELECT trial proved benefit in our age group. You deserve to feel good in your body regardless of age.

40 13nick_newbie, DadBodDave, AmyNC_wife and 37 others
Reply Quote Save Share Report
VanRx_Mike
Member
678
2,890
May 2024
Vancouver, CA
Feb 21, 2025 at 2:05 PM#32
josh_phd_bmore said:
Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history.

Thank you — that is the clearest version of this I have read, and I have read a lot of them.

Last edited: Feb 21, 2025 at 5:05 PM
41 14MikeNYC_runner and 38 others
Reply Quote Save Share Report
sarah_TO
Member
278
1,234
Sep 2024
Toronto, CA
Mar 2, 2025 at 10:21 AM#33

Adding the clinical framing, because it changes how the question reads.

Lp(a) and cardiovascular risk: a nuance that matters. Unlike most lipid markers, Lp(a) is 90%+ genetically determined and doesn't really change with weight loss or GLP-1 therapy.

My Lp(a) has remained at 42 nmol/L across all time points. If yours is elevated (>50 nmol/L), you need additional risk mitigation strategies regardless of your GLP-1 response. Don't assume your medication is covering all cardiovascular risk factors.

Last edited: Mar 2, 2025 at 2:21 PM
42 15GraceAZ_72, carl_compliance, DanielChem_CHI and 39 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
matt_MKE
Member
312
1,345
Sep 2024
Milwaukee, WI
Mar 11, 2025 at 6:32 AM#34
sarah_TO said:
Lp(a) and cardiovascular risk: a nuance that matters.

Adding a me-too, because a thread of one person's experience is not much use. I had assumed I was the exception until I read this.

43 16carl_compliance, DanielChem_CHI, marco_milano and 40 others
Reply Quote Save Share Report
LondonLisa
Member
912
3,456
Mar 2024
London, UK
Mar 20, 2025 at 2:37 AM#35
sarah_TO said:
Lp(a) and cardiovascular risk: a nuance that matters.

There is a second half to this that has not been said yet. Start from the measurement rather than the conclusion. Almost every disagreement here turns out to be two people measuring different things and comparing the numbers anyway.

44 17SallyK_inj, CryptoCarl, MariaRD and 41 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register